STOK - Stoke Therapeutics Inc Stock Price, Fair Value and News

$15.15-0.07 (-0.46%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

STOK RSI Chart

STOK Valuation

Market Cap

801.3M

Price/Earnings (Trailing)

-7.74

Price/Sales (Trailing)

52.87

Price/Free Cashflow

-9.94

STOK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

STOK Fundamentals

STOK Revenue

Revenue (TTM)

15.2M

Rev. Growth (Yr)

14.21%

Rev. Growth (Qtr)

14.59%

STOK Earnings

Earnings (TTM)

-103.6M

Earnings Growth (Yr)

16.18%

Earnings Growth (Qtr)

2.57%

STOK Price Action

Last 7 days

3.3%

Last 30 days

2.6%

Last 90 days

3.2%

Trailing 12 Months

220.0%

STOK Profitability

Return on Equity

-42.67%

Return on Assets

-33.65%

Free Cashflow Yield

-10.06%

STOK Financial Health

Current Ratio

6.67

STOK Investor Care

Shares Dilution (1Y)

18.96%

Diluted EPS (TTM)

-2.18

STOK Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	12.0M	15.2M	0	0
2023	14.6M	12.6M	10.7M	8.8M
2022	0	0	0	12.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.

CEO	Dr. Edward M. Kaye M.D., Ph.D.
WEBSITE	stoketherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	117

Stoke Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Stoke Therapeutics Inc? What does STOK stand for in stocks?

STOK is the stock ticker symbol of Stoke Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Stoke Therapeutics Inc (STOK)?

As of Wed Sep 18 2024, market cap of Stoke Therapeutics Inc is 801.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STOK stock?

You can check STOK's fair value in chart for subscribers.

Is Stoke Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether STOK is over valued or under valued. Whether Stoke Therapeutics Inc is cheap or expensive depends on the assumptions which impact Stoke Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STOK.

What is Stoke Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Sep 18 2024, STOK's PE ratio (Price to Earnings) is -7.74 and Price to Sales (PS) ratio is 52.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STOK PE ratio will change depending on the future growth rate expectations of investors.